摘要
目的:分析医院鲍曼不动杆菌感染患者的标本来源、科室分布及其耐药情况。方法:选取吉安市中心人民医院2020年1月—12月收治的住院患者320例各标本中分离出的鲍曼不动杆菌的病历资料,分析其各标本的细菌培养、分离、鉴定与药敏试验结果,以及标本的来源、分布及鲍曼不动杆菌的耐药情况。结果:320例鲍曼不动杆菌感染患者标本中,分离出鲍曼不动杆菌320株,标本主要来自痰液占68.12%,其次为分泌物(6.56%)和血液(5.62%);药敏结果发现鲍曼不动杆菌对头孢他啶的耐药率高达95.91%,对哌拉西林的耐药率为88.96%,对头孢曲松的耐药率为88.36%;痰标本中的鲍曼不动杆菌对抗菌药物的耐药率为最高,其次为胸腹水、分泌物中的鲍曼不动杆菌;血液中的鲍曼不动杆菌对抗菌药物的耐药率为最低;痰标本中鲍曼不动杆菌对哌拉西林、头孢曲松、头孢他啶、环丙沙星的耐药率均高于90.00%;胸腹水标本中鲍曼不动杆菌对哌拉西林、左氧氟沙星、环丙沙星、亚胺培南、头孢吡肟、头孢曲松、头孢他啶、哌拉西林-他唑巴坦钠、头孢哌酮-舒巴坦均高于90.00%;分泌物标本中鲍曼不动杆菌对亚胺培南、哌拉西林、头孢曲松、庆大霉素、环丙沙星的耐药率均高于70.00%。结论:2020年医院鲍曼不动杆菌在临床各科室和患者各年龄段中均有分布,且具有较高的耐药率;医院应定期监测病原菌的分布及其耐药情况,以指导临床抗菌药物的使用,减少耐药菌株的产生。
Objective: To analyze the specimen source, department distribution and drug resistance of Acinetobacter baumannii in patients with Acinetobacter baumannii infected. Methods: The medical records of Acinetobacter baumannii isolated from 320 hospitalized patients from January to December 2020 were selected to analyze the bacterial culture, isolation, identification and drug sensitivity test results of each specimen, as well as the source, distribution of specimens and the drug resistance of Acinetobacter baumannii. Results: Among 320 Acinetobacter baumannii infected patients, 320 strains of Acinetobacter baumannii were isolated, 68.12% of which were mainly from sputum, followed by secretions(6.56%) and blood(5.62%). Drug sensitivity results showed that the drug resistance rate of Acinetobacter baumannii to ceftazidime was up to 95.91%, the drug resistance rate to piperacillin was 88.96%, the drug resistance rate to ceftriaxone was 88.36%. The resistance rate of Acinetobacter baumannii in sputum specimens was the highest, followed by Acinetobacter baumannii in pleural and abdominal fluid and secretions. The resistance rate of Acinetobacter baumannii to antibiotics in blood was the lowest. The drug resistance rates of Acinetobacter baumannii to piperacillin, ceftriaxone, ceftazidime and ciprofloxacin in sputum specimens were all higher than 90.00%. The effects of Acinetobacter baumannii on piperacillin, levofloxacin, ciprofloxacin, imipenem, cefepime, ceftriaxone, ceftazidime, piperacillin-tazobactam, cefoperazone-sulbactam in pleural and abdominal fluid samples were higher than 90.00%. The drug resistance rates of Acinetobacter baumannii to imipenem, piperacillin, ceftriaxone, gentamicin and ciprofloxacin in secretions were all higher than 70.00%.Conclusion: In 2020, Acinetobacter baumannii is distributed in all clinical departments and patients of all ages, and has high drug resistance rates. Hospitals should regularly monitor the distribution and drug resistance of pathogenic bacteria so as to guide the use of antibacterials in clinic and reduce the emergence of drug resistant strains.
作者
李少芬
LI Shao-fen(Clinical Laboratory,Ji'an Central People's Hospital,Ji'an Jiangxi 343000,China)
出处
《抗感染药学》
2021年第10期1436-1440,共5页
Anti-infection Pharmacy
关键词
鲍曼不动杆菌
临床分布
耐药情况
抗菌药物
Acinetobacter baumannii
clinical distribution
drug resistance
antibacterial agents
